Drugs

Papers
(The H4-Index of Drugs is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Acknowledgement to Referees503
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”322
Targeting DNA Damage Response Deficiency in Thoracic Cancers285
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema270
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression232
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments206
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences177
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using174
Eftrenonacog Alfa: A Review in Haemophilia B171
Spesolimab for the Treatment of Generalized Pustular Psoriasis158
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations154
Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms149
Senaparib: First Approval142
New Therapies on the Horizon for Primary Biliary Cholangitis135
Vorasidenib: First Approval131
Aprocitentan: First Approval114
Teclistamab: First Approval111
Epcoritamab: First Approval108
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled,107
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial99
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments99
Drugs in Development to Manage Acute Pain97
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure96
Tolebrutinib: First Approval95
Efficacy and Harms of Opioid Analgesics for Acute Pain: Overview of Systematic Reviews and Meta-analyses92
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms92
Danicopan: First Approval91
Repotrectinib: First Approval86
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies86
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer84
Acoltremon: First Approval83
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?82
Cosibelimab: First Approval81
Androgenetic Alopecia: Therapy Update79
Lenacapavir: First Approval79
Ivarmacitinib Sulfate: First Approval78
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine74
Cancer Pain Treatment Strategies in Patients with Cancer72
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids72
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?70
Sibeprenlimab: First Approval69
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?69
Mazdutide: First Approval68
Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians66
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema65
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification65
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection63
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough62
Pozelimab: First Approval61
Correction to: Tapinarof Cream 1%: First Approval60
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes60
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?59
Taletrectinib: First Approval57
Ifupinostat: First Approval55
0.90262389183044